NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$177.4m

Last Updated

2021/09/18 22:14 UTC

Data Sources

Company Financials

Executive Summary

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Tyme Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TYME is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: TYME's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-3.7%

TYME

0.5%

US Biotechs

-0.6%

US Market


1 Year Return

2.0%

TYME

25.9%

US Biotechs

33.8%

US Market

Return vs Industry: TYME underperformed the US Biotechs industry which returned 25.7% over the past year.

Return vs Market: TYME underperformed the US Market which returned 33.8% over the past year.


Shareholder returns

TYMEIndustryMarket
7 Day-3.7%0.5%-0.6%
30 Day4.2%5.5%2.0%
90 Day-20.2%7.8%4.7%
1 Year2.0%2.0%27.5%25.9%35.8%33.8%
3 Year-56.9%-56.9%20.4%14.9%60.0%50.1%
5 Year-69.7%-69.7%48.9%37.2%123.0%98.7%

Long-Term Price Volatility Vs. Market

How volatile is Tyme Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tyme Technologies undervalued compared to its fair value and its price relative to the market?

1.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TYME's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TYME's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TYME is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: TYME is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TYME's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TYME is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Tyme Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

8.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tyme Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Tyme Technologies performed over the past 5 years?

-14.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TYME is currently unprofitable.

Growing Profit Margin: TYME is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TYME is unprofitable, and losses have increased over the past 5 years at a rate of 14.8% per year.

Accelerating Growth: Unable to compare TYME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: TYME has a negative Return on Equity (-27.03%), as it is currently unprofitable.


Financial Health

How is Tyme Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: TYME's short term assets ($74.7M) exceed its short term liabilities ($4.6M).

Long Term Liabilities: TYME's short term assets ($74.7M) exceed its long term liabilities ($2.0M).


Debt to Equity History and Analysis

Debt Level: TYME is debt free.

Reducing Debt: TYME has no debt compared to 5 years ago when its debt to equity ratio was 6.4%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TYME has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: TYME has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 25.8% each year.


Dividend

What is Tyme Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TYME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TYME's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TYME's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Richie Cunningham (50 yo)

0.83

Tenure

US$1,851,312

Compensation

Mr. Richard Cunningham, also known as Richie, serves as Chief Executive Officer and Director at Tyme Technologies, Inc. since November 24, 2020. Mr. Cunningham had been the Chief Executive Officer and Pres...


CEO Compensation Analysis

Compensation vs Market: Richie's total compensation ($USD1.85M) is above average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Insufficient data to compare Richie's compensation with company performance.


Leadership Team

Experienced Management: TYME's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: TYME's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TYME insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.7%.


Top Shareholders

Company Information

Tyme Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tyme Technologies, Inc.
  • Ticker: TYME
  • Exchange: NasdaqCM
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$177.373m
  • Shares outstanding: 172.21m
  • Website: https://www.tymeinc.com

Number of Employees


Location

  • Tyme Technologies, Inc.
  • 1 Pluckemin Way
  • Suite 103
  • Bedminster
  • New Jersey
  • 7921
  • United States

Listings


Biography

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial t...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/18 22:14
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.